08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Qiagen sales and marketing update

Qiagen launched the careHPV Test in India to detect high-risk HPV. The product is a test for 14 strains of HPV that does not require electricity or running water and is intended for use...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

CareHPV regulatory update

Qiagen said China's State Food and Drug Administration (SFDA) approved the careHPV test and its instrument platform to screen for high-risk strains of HPV that could lead to cervical cancer. The test does not require...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

HPV E6 test: Interim data

Interim data from 3,179 evaluable women in the Chinese START-UP trial showed that Arbor Vita's HPV E6 Test had 99% specificity and 69.6% sensitivity for detecting CIN3+ precancerous lesions. Comparatively, visual inspection of the cervix...
00:58 , Sep 20, 2011 |  BC Extra  |  Clinical News

Arbor Vita reports HPV test data

Arbor Vita Corp. (Fremont, Calif.) said its HPV E6 Test had 99% specificity and 69.6% sensitivity for detecting CIN3+ precancerous lesions in a trial to diagnose cervical cancer and cervical intraepitheleal neoplasia (CIN) precancerous lesions....
00:31 , Sep 14, 2011 |  BC Extra  |  Politics & Policy

Women's cancer initiative launched in Africa and Latin America

A group of government, public and private partners led by the George W. Bush Institute launched the Pink Ribbon Red Ribbon (PRRR) initiative to expand the availability of cervical cancer screening and treatment and promote...
07:00 , May 2, 2011 |  BC Week In Review  |  Company News

Qiagen, Merck infectious news

Merck and Qiagen will provide HPV vaccination and screening in Rwanda under the partners' cervical cancer prevention program initiated in 2009. Merck will provide more than 2 million doses of its Gardasil HPV vaccine...
23:49 , Apr 25, 2011 |  BC Extra  |  Company News

Merck, Qiagen launch HPV program in Rwanda

Merck & Co. Inc. (NYSE:MRK) and Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) will provide HPV vaccination and screening in Rwanda under the partners' cervical cancer prevention program initiated in 2009. Merck will provide more than two million...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Clinical News

CareHPV regulatory update

Qiagen received CE Mark approval in the EU for careHPV to test for 14 high-risk strains of HPV that could lead to cervical cancer. The test does not require access to electricity or running water...